Contraceptive Technology Update – February 1, 2016
February 1, 2016
View Issues
-
Survey results show use of LARC continues to rise
About 46% of participants in the 2015 Contraceptive Technology Update Contraception Survey say they have seen “dramatically more” women choosing long-acting reversible contraceptive methods such as the intrauterine device and contraceptive implant in the last year.
-
Survey profile
The 2015 Contraceptive Technology Update Contraception Survey monitors contraceptive trends and family planning issues among readers. Results were tallied and analyzed by AHC Media in Atlanta, which publishes CTU and dozens of other healthcare newsletters and sourcebooks and presents webinars and conferences.
-
Focus on the contraceptive implant — Insert it in your family planning practice
About 30% of participants in the 2015 Contraceptive Technology Update Contraception Survey reported 25 or more implant insertions in the past year, with 14% saying they inserted 11 to 24 devices.
-
Should oral contraceptives move over the counter? Readers speak out
Most participants in the Contraceptive Technology Update Contraception Survey say they support moving oral contraceptives over the counter. Almost 50% say they would support OTC availability of progestin-only pills, while 32% say they would support similar availability of combined hormonal pills.
-
Where do pills fit in the family planning picture?
In national statistics, the pill continues to lead the pack, with 25.9% of contracepting women (9.7 million women) reporting its use. Female sterilization was listed by 25.1% (9.4 million women), followed by the male condom (15.3%, 5.8 million women) and long-acting reversible contraception (11.6%, 4.4 million women).
-
Chlamydia, gonorrhea, and syphilis cases are up for first time since 2006
Reported cases of chlamydia, gonorrhea, and syphilis have increased for the first time since 2006, according to just-published data by the Centers for Disease Control and Prevention.
-
HPV vaccine update: Get up to speed
Healthcare professionals need to be familiar with all of the indications for the human papillomavirus vaccine, make strong recommendations for receiving vaccine at ages 11 or 12, and be aware of systems that can improve practice vaccination rates.